Abstract
The efficacy and cost/performance benefit of radionuclide bone scintigraphy in monitoring metastatic bone activity remain controversial. Recently developed bone metabolic markers are expected to play an additional role in the diagnosis of bone metastasis. We measured osteoclastic and osteoblastic markers in 267 patients with breast cancer (100 with bone metastasis), 38 patients with prostatic cancer (25 with bone metastasis), 50 patients with lung cancer (12 with bone metastasis) and 33 patients with miscellaneous cancers (13 with bone metastasis) and compared the values in the presence and absence of bone metastasis. Bone metabolic markers, both osteoclastic and osteoblastic, increased significantly in patients with bone metastasis. In breast cancer (bone metastasis is mostly of the mixed type), osteoclastic markers were good in detecting bone metastasis. In prostatic cancer (bone metastasis is mostly osteoblastic), osteoclastic and osteoblastic markers were equally effective in detecting bone metastasis. In lung cancer (bone metastasis is mostly osteolytic), osteoclastic markers were elevated preferentially in bone metastasis. Over all, osteoclastic markers were more sensitive in the diagnosis of bone metastasis, and among osteoclastic markers, serum pyridionoline-cross-linked carboxyterminal telopeptide was the most efficient in both specificity (91.0%) and sensitivity (48.6%) for detecting bone metastasis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- BGP :
-
bonegla protein
- ICTP :
-
pyridinoline-cross-linked carboxyterminal telopeptide
- Dpd :
-
deoxypyridinoline
- PICP :
-
procollagen I carboxyterminal peptide
References
Abrams HL, Spiro R, Goldstein N (1950) Metastases in carcinomas: analysis of 1000 autopsied cases. Cancer 3: 74–85
Coleman RE, Houston S, James I, Rodger A, Rubens RD, Leonard RCF, Ford J (1992) Preliminary results of the use of urinary excretion of pyridium crosslinks for monitoring metastatic bone disease. Br J Cancer 65: 766–768
Eyre DR, Koob TJ, Van Ness KP (1984) Quantitation of hydroxypyridium crosslinks in collagen by high-performance liquid chromatography. Anal Biochem 137: 380–388
Garnero P, Gineyts E, Riou JP, Delmas PD (1994) Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79: 780–785
Janicek MJ, Hayes DF, Kaplan WD (1994) Healing flare in skeletal metastases from breast cancer. Radiology 192: 201–204
Melkko J, Niemi S, Risteli L, Risteli J (1990) Radioimmunoassay of carboxyterminal propeptide of human type I procollagen. Clin Chem 36: 1328–1332
Perez DJ, Powles TJ, Milan J, Gazet JC, Ford HT, McCready VR, MacDonald JS, Coombes RC (1983) Detection of breast carcinoma metastases in bone: relative merit of X-rays and skeletal scintigraphy. Lancet II: 613–616
Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L (1993) Radio-immunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen. Clin Chem 39: 635–640
Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ (1994) Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9: 1643–1649
Woolfenden JM, Pitt MJ, Durie BGM, Moon TE (1980) Comparison of bone scintigraphy in multiple myeloma. Radiology 134: 723–728
Author information
Authors and Affiliations
Additional information
Work dedicated to Dr. Haruo Sugano on the occasion of his 70th birthday. The material of this paper was essentially presented at the 60th Anniversary Symposium of the Cancer Institute and the Cancer Institute Hospital, Tokyo, held in September 1994
Rights and permissions
About this article
Cite this article
Koizumi, M., Yamada, Y., Takiguchi, T. et al. Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol 121, 542–548 (1995). https://doi.org/10.1007/BF01197767
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01197767